Clinical efficacy of Lactobacillus reuteri-containing lozenges in the supportive therapy of generalized periodontitis stage III and IV, grade C: 1-year results of a double-blind randomized placebo-controlled pilot study

Objective The aim of this 12-month mono-centre double-blind randomized placebo-controlled clinical study was to evaluate the efficacy of Lactobacillus reuteri -containing lozenges during the supportive therapy of generalized periodontitis stage III and IV, grade C (GPIII-IVC) patients. Material and...

Full description

Saved in:
Bibliographic Details
Published in:Clinical oral investigations 2020-06, Vol.24 (6), p.2015-2024
Main Authors: Grusovin, Maria Gabriella, Bossini, Simone, Calza, Stefano, Cappa, Veronica, Garzetti, Gianluca, Scotti, Eleonara, Gherlone, Enrico Felice, Mensi, Magda
Format: Article
Language:English
Subjects:
Clinical trials
Dentistry
Double-blind studies
Gum disease
Lactobacillus reuteri
Medicine
Original Article
Patients
Periodontitis
Probiotics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective The aim of this 12-month mono-centre double-blind randomized placebo-controlled clinical study was to evaluate the efficacy of Lactobacillus reuteri -containing lozenges during the supportive therapy of generalized periodontitis stage III and IV, grade C (GPIII-IVC) patients. Material and methods Twenty treated GPIII-IVC patients were randomly divided into 2 groups. The test group received two 3-month-long administrations of L. reuteri (2 lozenges/day after brushing) with a 3-month washout period, while the control one received a placebo. Outcome measures were tooth survival, complications and adverse events, change in probing pockets depth (PPD), change in probing attachment level (PAL), presence of bleeding on probing (BOP) and patient’s evaluation of treatment. Measurements were collected at 3, 6, 9 and 12 months. Results At 1 year, no dropout, tooth loss, complications or adverse event were recorded. Mean PPD and mean PAL and percentages of sites with BOP were statistically improved ( p  
ISSN:1432-6981
1436-3771
DOI:10.1007/s00784-019-03065-x